For Life Sciences
Ensuring easy and fast access to real-world data.

request a demo

ADDED VALUE FOR LIFE SCIENCES

Generation of High-Quality Real-World Evidence

The platform provides real-world patient data to generate robust and relevant evidence. This enhances the credibility and validity of studies, facilitating regulatory approval and the adoption of new treatments in the market​.

Faster Time-to-Market

With rapid data availability and automated mediation process, data users can reduce the time required to initiate and complete research, commercialization and policy-making initiatives.

Ease of Use and Immediate Access

An easy-to-use, subscription-based platform allowing access to secure and compliant RWD, removing the need for manual data collection and administrative bureaucracy.

Access to a Large Federated Network of Hospitals

IOMED federated network of hospitals provides unparalleled, diverse and comprehensive patient data. This growing network enables to conduct multicenter studies more efficiently, ensuring a wide representation of patient populations.

Flexibility to Request Any Type of RWD in a Predictable Cost Model

Request additional health data on an as-needed basis. The flexibility of the subscription model provides for a complete control of costs.

Integrated Compliance and Security

The Data Space Platform adheres to rigorous compliance processes ensuring strict privacy and security regulations are respected.
FOR WHOM
1
Clinical Development & Strategy
Design better studies from day one using real clinical data, identify the right patient populations and endpoints based on real-world practice, and reduce uncertainty in early development decisions.
2
Biostatistics & Data Science
Start with analysis-ready, structured clinical data, confirm variable availability and data quality before defining the analysis, and build robust models on longitudinal, high-quality data.
3
Clinical Trials
Assess real feasibility with accurate patient counts and cohort characterization, identify hospitals with eligible patients and sufficient volume, and optimize inclusion/exclusion criteria to maximize recruitment.
4
Clinical Operations
Select sites based on real patient data, not assumptions, accelerate recruitment through precise patient identification, amd improve tracking with structured, longitudinal clinical data.
5
RWE / HEOR / Epidemiology
Generate robust evidence from real, harmonized clinical data across hospitals, build observational studies and external control arms with clinical depth, and support access and value decisions with validated, traceable data.
6
Medical Affairs
Strengthen publications with real-world clinical evidence, generate insights on treatments, outcomes, and patient journeys, adn ngage clinicians with relevant, data-driven insights.

Success Stories

Accelerating Rare Disease Diagnosis: A Patient Identification Project for Alport Syndrome.

Fundació Puigvert leads a multicentric study aiming to identify undiagnosed patients through AI-powered phenotyping and real-world data.
This study, led by Hospital Fundació Puigvert in collaboration with IOMED, harnessed the power of real-world data (RWD) and artificial intelligence (AI) to support earlier detection of HKDs like Alport Syndrome. By helping physicians find patients whose conditions might otherwise go unnoticed, the study opens the door to faster diagnosis and better care.

Artificial Intelligence for Identifying CAR-T Therapy Candidates Using Real-World Data

A pilot study by the spanish hematopoietic transplant and cellular therapy group (GETH-TC)
This pilot study, conducted by the Spanish Hematopoietic Transplant and Cellular Therapy Group (GETH-TC) in collaboration with IOMED, introduces an artificial intelligence (AI)-driven system using real-world data (RWD) to improve patient identification for CAR-T therapy, reducing missed candidates and accelerating treatment timelines

Optimizing Thyroid Cancer Research with Real-World Data and NLP: The NATI Study

Unlocking clinical insights through AI-powered data extraction from unstructured medical records.
The NATI study (NATural language in ThyroId cancer), aimed to provide an updated, real-world view of how thyroid cancer is diagnosed and managed in clinical practice by analyzing patient data from 4 Spanish hospitals.
RECOGNITIONS AND CERTIFICATIONS
ISO 9001:2015
ISO 27001:2022
ISO 27701:2019
Client Iqvia
Client GSK
Client Vifor
Client AstraZeneca
Clients BMS
Clients BC Platforms
Client AMADIX
Top 50 CB Insights
EU Seal of Excellence
EHDEN Certified SME
OHDSI Partners
ISO 9001:2015
ISO 27001:2022
ISO 27701:2019
Top 50 CB Insights
EU Seal of Excellence
EHDEN Certified SME
OHDSI Partners